Literature DB >> 21537340

When versatility matters: activins/inhibins as key regulators of immunity.

G R Aleman-Muench1, G Soldevila.   

Abstract

Activins and inhibins are members of the transforming growth factor-β superfamily that have been considered crucial regulators of cell processes, such as differentiation, proliferation and apoptosis, in different cell types. Initial studies about the function of activin A in the immune system focused on the regulation of hematopoiesis in the bone marrow under homeostatic and inflammatory conditions. Recent data provide a more comprehensive understanding about the role of activins/inhibins in the immune system. Novel findings included in this review point out the important requirement of activin/inhibin signaling to maintain the balance between homeostatic and inflammatory signals that are required for the optimal development and function of immune cells. The purpose of this review is to highlight the versatile nature of activins/inhibins as key regulators of both the innate and adaptive immune responses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21537340     DOI: 10.1038/icb.2011.32

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  31 in total

Review 1.  Effects of bone matrix proteins on fracture and fragility in osteoporosis.

Authors:  Grażyna E Sroga; Deepak Vashishth
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

Review 2.  Immunoregulation by members of the TGFβ superfamily.

Authors:  WanJun Chen; Peter Ten Dijke
Journal:  Nat Rev Immunol       Date:  2016-11-25       Impact factor: 53.106

3.  Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.

Authors:  Kyosuke Hino; Kazuhiko Horigome; Megumi Nishio; Shingo Komura; Sanae Nagata; Chengzhu Zhao; Yonghui Jin; Koichi Kawakami; Yasuhiro Yamada; Akira Ohta; Junya Toguchida; Makoto Ikeya
Journal:  J Clin Invest       Date:  2017-07-31       Impact factor: 14.808

4.  Interaction of menstrual cycle phase and sexual activity predicts mucosal and systemic humoral immunity in healthy women.

Authors:  Tierney K Lorenz; Gregory E Demas; Julia R Heiman
Journal:  Physiol Behav       Date:  2015-09-21

5.  Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent.

Authors:  Sayantani Sinha; Kenta Uchibe; Yu Usami; Maurizio Pacifici; Masahiro Iwamoto
Journal:  Bone       Date:  2016-02-15       Impact factor: 4.398

Review 6.  Chasing the recipe for a pro-regenerative immune system.

Authors:  James W Godwin; Alexander R Pinto; Nadia A Rosenthal
Journal:  Semin Cell Dev Biol       Date:  2016-08-10       Impact factor: 7.727

7.  BAFF and APRIL from Activin A-Treated Dendritic Cells Upregulate the Antitumor Efficacy of Dendritic Cells In Vivo.

Authors:  Michael R Shurin; Yang Ma; Anton A Keskinov; Ruijing Zhao; Anna Lokshin; Marianna Agassandian; Galina V Shurin
Journal:  Cancer Res       Date:  2016-06-30       Impact factor: 12.701

8.  ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.

Authors:  Sarah J Hatsell; Vincent Idone; Dana M Alessi Wolken; Lily Huang; Hyon J Kim; Lili Wang; Xialing Wen; Kalyan C Nannuru; Johanna Jimenez; Liqin Xie; Nanditha Das; Genevieve Makhoul; Rostislav Chernomorsky; David D'Ambrosio; Richard A Corpina; Christopher J Schoenherr; Kieran Feeley; Paul B Yu; George D Yancopoulos; Andrew J Murphy; Aris N Economides
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

Review 9.  Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.

Authors:  Maurizio Pacifici; Eileen M Shore
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-28       Impact factor: 7.638

Review 10.  Granting immunity to FOP and catching heterotopic ossification in the Act.

Authors:  Frederick S Kaplan; Robert J Pignolo; Eileen M Shore
Journal:  Semin Cell Dev Biol       Date:  2015-12-17       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.